Related Experiment Video

Updated: Oct 21, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K

Loss of Neurologic Reserve in Progressive Multiple Sclerosis: A Paradigm Shift?

Joep Killestein1, Maria Liguori1

  • 1Amsterdam UMC (JK), Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, the Netherlands; and National Research Council (CNR) (ML), Institute of Biomedical Technologies, Bari Unit, Italy.

Neurology. Clinical Practice
|September 6, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.2K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.2K

Related Experiment Videos

Last Updated: Oct 21, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.2K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.2K

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

865
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
865
Neuroplasticity01:01

Neuroplasticity

954
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
954
Neural Regulation01:37

Neural Regulation

40.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.6K

Articles linked to this work by shared authors, journal, and citation graph.

Sex-dependent bioactive lipid mediator profiles in multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026

The value of brain age as a transdiagnostic biomarker of neurodegeneration.

medRxiv : the preprint server for health sciences·2026

Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.

Neurology·2026

Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis.

Multiple sclerosis and related disorders·2026

Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis.

Science translational medicine·2026

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

European journal of neurology·2026

The Menopause Transition and Epilepsy: A Focus on Therapeutics.

Neurology. Clinical practice·2026

Harmonizing Multi-Institutional Clinical Documentation Using Natural Language Processing in Neurofibromatosis Type 1.

Neurology. Clinical practice·2026

Establishing a Transition Program for Young Adults With Epilepsy.

Neurology. Clinical practice·2026

Psychiatric Outcomes of Antiseizure Medications in Newly Diagnosed Focal Onset Epilepsy: From the Human Epilepsy Project Cohort Study.

Neurology. Clinical practice·2026

Three-Year Mortality After First Acute Symptomatic Seizure: A Prospective, Population-Based Study in Ireland.

Neurology. Clinical practice·2026

A Faster Way to Diagnose Multiple Sclerosis: The Central Vein Sign in Routine Clinical Practice.

Neurology. Clinical practice·2026

Neuroprotection of engineered Clostridium butyricum-pMTL007-GLP-1 in A53T α-synuclein (α-syn) mouse model via PI3K/AKT/GSK-3β.

Journal of Zhejiang University. Science. B·2026

Incidence and clinical characteristics of amyotrophic lateral sclerosis during the post-COVID-19 Period: a population-based study from Isfahan, Iran.

Neurodegenerative disease management·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us